Summary A new bisphosphonate, disodium dihydrogen (cycloheptylamino) methylene bisphosphonate monohydrate (YM175), was compared with 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (AHPrBP) and l-hydroxyethylidene-1,1-bisphosphonate (HEBP) in terms of its effect on tumour induced osteolysis using a bladder tumour in mice (MBT-2). The method consisted of inoculating tumour cells subcutaneously (SC) (Fleisch et al., 1969; Fleisch & Felix, 1979; Fleisch, 1983) . Inhibition of tumour induced osteolysis by bisphosphonates has been noted in animal and human studies (Jung et al., 1981; VanHoltenVerzantvoort et al., 1987; Morton & Howell, 1988) .
There are at least two mechanisms for osteolysis that occurs in both human metastases and experimental skeletal metastasis; osteoclast mediated bone destruction and direct destruction of bone independent of osteoclasts (Galasko & Bennett, 1976) . Thus, agents that inhibit bone resorption might be used to decrease the extent of bone destruction by the tumour. Based on their action on calcium phosphate crystal formation and on bone resorption, bisphosphonates represent a new class of drugs with considerable therapeutic potential for metastatic bone disease (Fleisch et al., 1969; Fleisch & Felix, 1979; Fleisch, 1983) . Inhibition of tumour induced osteolysis by bisphosphonates has been noted in animal and human studies (Jung et al., 1981; VanHoltenVerzantvoort et al., 1987; Morton & Howell, 1988) .
With regard to experimental model systems of neoplasmassociated local osteolysis, tumour-bone interactions using calvaria of the mice were extensively studied by our group (Nemoto et al., 1986; Nemoto et al., 1987; Nemoto et al., 1988a; Nemoto et al., 1988b) . In one of the recent studies, suggestive evidence was obtained that our system might be suitable for studying the biology of local interaction between bone and cancer cells. Furthermore, it is suggested that bone destruction induced by tumour cell invasion involves at least two mechanisms; osteoclast mediated bone destruction, and direct destruction of bone independent of osteoclasts. Bisphosphonate makes bone less susceptible to the action of both osteoclasts and tumour cells (Nemoto et al., 1992) .
In this paper, a new more powerful bisphosphonate, YM175 was investigated and compared to both AHPrBP and HEBP using as a model of osteolysis induced by MBT (Soloway, 1977) . The tumour has retained the histologic appearance of a poorly differentiated transitional cell carcinoma. TSU-PRI is a cell line derived from a primary adenocarcinoma of the prostate in a 73-year-old man with multiple osteoblastic bone metastases (Nemoto et al., 1988b Radiographs were examined in blind conditions. The area of bone resorption from radiograph detectable lesions was measured by computerised analysis using graphtec software for plotters. After decalcification by EDTA, the same samples were processed for histologic examination.
Treatment
The following bisphosphonates were used: YM175: disodium dihydrogen (cycloheptylamino) methylene bisphosphonate monohydrate, AHPrBP: 3-amino-1-hydroxypropylidene-1,1-bisphosphonate, and HEBP: 1-hydroxyethylidene-1, 1-bisphosphonate. YM175, HEBP and AHPrBP were synthesised by the Department of Pharmacology, Medical Research Laboratories, Central Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd. in Japan. Eel calcitonin (Sigma) was dissolved in 0.05% NaCl and 0.2% sodium acetate in distilled water containing 1 mg ml-' of bovine albumin (Sigma). The bisphosphonates were dissolved in 0.9% NaCl solution and injected SC into the flanks. The doses and schedule are specified in the tables and figures. Control animals were given the solvent.
Statistical analysis
The data were analysed by one-way analysis of variance to detect differences between groups. When difference were detected (P <0.05), Fisher's multiple range test was used to determine the significance. All values are presented as mean ± s.d.
Results
If the tumour was not grown or not larger than 10 mm, the mice were excluded from additional evaluation as judged by radiography and histological examination.
The effects of various types of bisphosphonates and calcitonin on bone resorption induced by MBT-2 tumours in mice assessed by graphtec software for plotters in radiographs are presented in Table I (Table II) . The administration of 0.3 mg kg-' of YM 175 every 3 days significantly reduced bone resorption (P < 0.01). Total dose of 6.0 mg kg-' YM-175 was administered by the interval of every 5 days (1.5 mg kg-' day-') and 10 days (3.0 mg kg-' day-'). The inhibitory effect was significant.
The compounds were active not only when administered preventively before the establishment of bone resorption, but also when administered after the tumour began influencing the bone (Figure la,b,c,d ). Table III 27.2 ± 13.5 24.5 aMean ± s.d. bDrugs were given from day 1 to completion of trial. cInhibition rate (%) = (1-control/treated) x 100. dp <0.001 as compared to control animals. aMean ± standard deviation. bDrugs were given from day 14 to completion of trial and mice were sacrificed at day 22. CP<0.01 as compared with control animals. dp <0.05 as compared with control animals.
a aMean ± s.d. bDrugs were given from day 1 to completion of trial. clnhibition rate (%) = (1-control/treated)) x 100. dP <0.001 as compared to control animals. 'P <0.01 as compared to control animals.
Discussion
The course of malignant disease is often associated with increased skeletal destruction and hypercalcemia. The efficacy of new drugs capable of inhibiting bone resorption can be assessed in several animal models of malignant osteolysis, including the VX2 carcinoma in rabbits, the Walker 256/B mammary carcinosarcoma and the prostate adenocarcinoma in rats (Galasko & Bennett, 1976; Jung, 1984; Pollard & Luckert, 1985) . We established a model of tumour-induced osteolysis using the MBT-2 tumour in mice (Nemoto et al., 1986; Nemoto et al., 1987) . Although it does not metastasise to bone, the tumour does cause marked osteolysis. It has been shown in the past that this model consists of inoculating MBT-2 tumour cells SC over the calvaria in mice, resulting in a local tumour causing fragmentation of the bone, which were evaluated by radiographic and histologic examination. The present study was performed to test the effect of drugs against tumour induced osteolysis using this model and it has been found to respond to bisphosphonates. In order to quantitatively assess the changes induced by the compounds, a method was developed to measure osteoclastic changes in X-p film using an automatic image analyser. Animal models have also been developed using human materials in this system (Nemoto et al., 1988b) . Experiment evidence on YM175 indicated that it was effective on hypercalcemia induced by parathyroid hormone as well as parathyroid related hormone plus IL-lb in the rat (Abe et al., 1989) . This agent was also effective on osteolysis induced by Walker carcinoma in rats (Kudo et al., 1990) . Our results clearly show that YM175 was effective in protecting bone lysis induced by MBT-2 bladder tumours of mice. This protection occurred without evidence of toxicity to the animals and it did not interfere with tumour growth. All three bisphosphonates tested, YM175, HEBP and AHPrBP, showed a similar effect, namely, a powerful reduction of the tumour-induced osteolysis as revealed by radiograph film and microscopic examination. The new bisphosphonate, YM175, displayed similar potency, but was more active than HEBP and AHPrBP. With YM175, this inhibition of tumour induced osteolysis was observed at a dose ten times lower than the level where the maximum effect on resorption had occurred with the other two drugs.
This agent has not been tested in vivo on bone resorption induced by human tumour cells. Our results show clearly that YM175 was effective in protecting osteolysis induced by human prostate cancer cells in nude mice. This protection occurred without evidence or toxicity to the animals and no interference with tumour growth.
In addition, other questions concerning the dose, the interval, the route of administration and the duration of treatment with bisphosphonates need to be answered. Little is known about the efficacy of these compounds in the treatment of established bone metastases. It is interesting to notice that the administration of one dose of YM175 was effective over a period of at least 5 days. For HEBP and AHPrBP, this effect was comparable with that obtained with daily injetions of 0.3 mg kg-' in MBT-2 tumour models. At these dosage levels, the effect was controlled by adjusting the interval between drug injections.
The compounds were active not only when administered preventively before the establishment of bone resorption, but also when administered after the tumour began influencing the bone. At present, the results suggest that osteolytic lesions may be in remission for at least 10 days when treatment with YM175 is halted. Further studies are needed to elucidate the mechanism by which YM175 protects tumour invasion of bones in this model.
The results of this study suggest the possibility of using new, very powerful bisphosphonate in malignant bone diseases with progressive bone destruction. In addition, the bisphosphonates may be administered for short periods or adjusting the interval between drug injection. The drugs are likely to be useful both in preventing the development of bone disease and in treating established lesions. However, further studies are required to determine the utility of this compound in the clinical implication.
